- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -
TEL AVIV, Israel and OSLO, Norway , May 22, 2026 /PRNewswire/ --Â BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology...
Management to Hold Conference Call at 8:30 a.m. EDT
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center
GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers Â
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -
Management to Hold Conference Call at 8:30 a.m. EDT
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -
Management to Hold Conference Call at 8:30 a.m. EST